An important finding on the stress-induced hormone hepatocyte was made by a team led by Professor Kezhong Zhang, Ph.D., of the Center for Molecular Medicine and Genetics and the Department of Biochemistry, Microbiology, and Immunology at Wayne State University School of Medicine.
The discovery has implications for treating hyperlipidemia and preventing related cardiovascular and metabolic disorders. Hyperlipidemia is a metabolic condition characterized by an accumulation of unhealthy fats in the blood. These fats include triglycerides and cholesterol. According to Dr. Zhang, hypertriglyceridemia, a disorder characterized by increased circulating triglyceride levels, is a widespread issue in the United States.
The risk of stroke, heart attack, and type 2 diabetes is raised in those with hypertriglyceridemia, which can be brought on by an unhealthy diet, an aberrant lifestyle, or environmental stress. Dr. Zhang and other researchers studying metabolic disorders are looking for strategies to safely reduce or deposit blood triglycerides in order to treat hyperlipidemia.
As a result of higher energy demands or stress challenges, like those generated by fasting, Dr. Zhang and colleagues identified a novel hepatocyte, a hormone derived from a membrane protein called CREBH. CREBH-C, the hepatocyte in question, has been shown to increase triglyceride breakdown and lower blood triglyceride and fatty acid levels.
The effects of stress on health and illness have been a long-term focus in Dr. Zhang’s lab. His research group at Wayne State University uncovered new information about the roles that cellular stress sensors and signaling pathways play in metabolic health and illness. He also noted that the recent discovery of the stress hormone CREBH-C showed promise as a therapeutic approach for modifying lipid metabolism in the treatment of cardiovascular and metabolic illnesses.
Associate Professor Ren Zhang, Ph.D., M.D., Research Associate Zhenfeng Song, Ph.D., and Assistant Professor Hyunbae Kim, Ph.D., all from Wayne State University, all contributed to the work. The WSU group worked with an associate professor and Ph.D. candidate in physics at the University of Iowa, Brandon Davies.
You can also check:-
- Charmian Carr Cause Of Death: Was She Died From Frontotemporal Dementia?
- Original Fox News Channel Anchor Uma Pemmaraju Dies at 64
Gender Affirming Hormone Therapy Reduces Depression And Anxiety For Trans And Non-binary Youth
Transgender and nonbinary youth who began gender-affirming hormone therapy reported a considerable improvement in the alignment of their gender and physical traits two years later, according to a big new study.
Adolescents who identify as transgender or nonbinary have a higher risk of suicidality, depression, and anxiety, and this study shows that gender-affirming hormone treatment can help.
From July 2016 through June 2019, 315 transgender and nonbinary youth between the ages of 12 and 20 participated in the study.
Clinics in Los Angeles’ Children’s Hospital, San Francisco’s UCSF Benioff Children’s Hospital, Boston’s Ann & Robert H. Lurie Children’s Hospital, and Chicago’s Ann & Robert H. Lurie Children’s Hospital all provided care. The study was financed by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
For more information visit Greenenergyanalysis.com.